Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIA-662 in Hypertriglyceridemia
NCT00758303Phase 3
Key facts
- Status
- Completed
- Start
- Sep 2007
- Primary completion
- Dec 2008
- Sponsor
- Cortria
- Modality
- Small Molecules
- Drugs
- 1-methylnicotinamide
- Conditions
- hypertriglyceridemia
01
Overview
Phase 3, randomised, double-blind trial of 1-methylnicotinamide in hypertriglyceridemia (3 arms), sponsored by Cortria. Primary endpoint: Percent change in total serum Triglycerides from baseline to end of study at 12 weeks. Started Sep 2007; status: completed.
02
Design
3 arms- Study design
- RandomizedDouble-blind
Low Dose TRIA-662
30 mg TRIA-662 three times daily
High Dose TRIA-662
90 mg TRIA-662 three times daily
Placebo
Matching Placebo for TRIA-662 taken 3 times a day
03
Who it enrols
Adult patients with hypertriglyceridemia or mixed hyperlipidemia (TG > 200 mg/dl and < 700 mg/dl) not receiving lipid lowering treatment.
04
Endpoints
Primary
Percent change in total serum Triglycerides from baseline to end of study
Secondary
Percent change in total cholesterol (TC)
Percent change in major lipoprotein sub-fractions
Effects on inflammatory markers
Beyond the preview
Go deeper on NCT00758303.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00758303.